#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=Lício Velloso
1-1	0-5	Lício	person[1]	new[1]	coref	7-1[10_1]
1-2	6-13	Velloso	person[1]	new[1]	_	_

#Text=Licio
2-1	14-19	Licio	person	new	_	_

#Text=Augusto
3-1	20-27	Augusto	person	new	_	_

#Text=Velloso
4-1	28-35	Velloso	place	new	coref	15-11

#Text=is a Brazilian full professor of medicine at the University of Campinas .
5-1	36-38	is	_	_	_	_
5-2	39-40	a	person[5]	new[5]	_	_
5-3	41-50	Brazilian	person[5]	new[5]	_	_
5-4	51-55	full	person[5]	new[5]	_	_
5-5	56-65	professor	person[5]	new[5]	_	_
5-6	66-68	of	person[5]	new[5]	_	_
5-7	69-77	medicine	person[5]|abstract[6]	new[5]|new[6]	_	_
5-8	78-80	at	person[5]|abstract[6]	new[5]|new[6]	_	_
5-9	81-84	the	person[5]|abstract[6]|organization[7]	new[5]|new[6]|new[7]	coref	7-10[15_7]
5-10	85-95	University	person[5]|abstract[6]|organization[7]	new[5]|new[6]|new[7]	_	_
5-11	96-98	of	person[5]|abstract[6]|organization[7]	new[5]|new[6]|new[7]	_	_
5-12	99-107	Campinas	person[5]|abstract[6]|organization[7]|place	new[5]|new[6]|new[7]|new	coref	7-13
5-13	108-109	.	_	_	_	_

#Text=Education
6-1	110-119	Education	abstract	new	_	_

#Text=Lício Velloso obtained his MD degree in 1986 from the University of Campinas .
7-1	120-125	Lício	person[10]	giv[10]	ana	7-4[0_10]
7-2	126-133	Velloso	person[10]	giv[10]	_	_
7-3	134-142	obtained	_	_	_	_
7-4	143-146	his	person|abstract[13]	giv|new[13]	ana	8-1
7-5	147-149	MD	place|abstract[13]	new|new[13]	_	_
7-6	150-156	degree	abstract[13]	new[13]	_	_
7-7	157-159	in	_	_	_	_
7-8	160-164	1986	time	new	_	_
7-9	165-169	from	_	_	_	_
7-10	170-173	the	organization[15]	giv[15]	coref	9-25[41_15]
7-11	174-184	University	organization[15]	giv[15]	_	_
7-12	185-187	of	organization[15]	giv[15]	_	_
7-13	188-196	Campinas	organization[15]|place	giv[15]|giv	coref	8-28
7-14	197-198	.	_	_	_	_

#Text=He then attended Uppsala University in Sweden from which he graduated in 1993 and then served as a postdoc at the Mario Saad Lab , University of Campinas and at the Ron Kahn Lab , Harvard University in 1994 and 1995 respectively . [ 1 ]
8-1	199-201	He	person	giv	ana	8-10
8-2	202-206	then	_	_	_	_
8-3	207-215	attended	_	_	_	_
8-4	216-223	Uppsala	place|organization[19]	new|new[19]	_	_
8-5	224-234	University	organization[19]	new[19]	_	_
8-6	235-237	in	organization[19]	new[19]	_	_
8-7	238-244	Sweden	organization[19]|place	new[19]|new	_	_
8-8	245-249	from	_	_	_	_
8-9	250-255	which	_	_	_	_
8-10	256-258	he	person	giv	ana	9-1
8-11	259-268	graduated	_	_	_	_
8-12	269-271	in	_	_	_	_
8-13	272-276	1993	time	new	_	_
8-14	277-280	and	_	_	_	_
8-15	281-285	then	_	_	_	_
8-16	286-292	served	_	_	_	_
8-17	293-295	as	_	_	_	_
8-18	296-297	a	_	_	_	_
8-19	298-305	postdoc	_	_	_	_
8-20	306-308	at	_	_	_	_
8-21	309-312	the	person[23]	new[23]	coref	8-31[26_23]
8-22	313-318	Mario	person[23]	new[23]	_	_
8-23	319-323	Saad	person[23]	new[23]	_	_
8-24	324-327	Lab	person[23]	new[23]	_	_
8-25	328-329	,	_	_	_	_
8-26	330-340	University	organization[24]	new[24]	appos	8-36[28_24]
8-27	341-343	of	organization[24]	new[24]	_	_
8-28	344-352	Campinas	organization[24]|place	new[24]|giv	coref	9-28
8-29	353-356	and	_	_	_	_
8-30	357-359	at	_	_	_	_
8-31	360-363	the	person[26]	giv[26]	_	_
8-32	364-367	Ron	person[26]	giv[26]	_	_
8-33	368-372	Kahn	person[26]	giv[26]	_	_
8-34	373-376	Lab	person[26]	giv[26]	_	_
8-35	377-378	,	_	_	_	_
8-36	379-386	Harvard	organization|organization[28]	new|giv[28]	_	_
8-37	387-397	University	organization[28]	giv[28]	_	_
8-38	398-400	in	organization[28]	giv[28]	_	_
8-39	401-405	1994	organization[28]|time	giv[28]|new	_	_
8-40	406-409	and	organization[28]	giv[28]	_	_
8-41	410-414	1995	organization[28]|time[30]	giv[28]|new[30]	_	_
8-42	415-427	respectively	organization[28]|time[30]	giv[28]|new[30]	_	_
8-43	428-429	.	_	_	_	_
8-44	430-431	[	_	_	_	_
8-45	432-433	1	abstract	new	_	_
8-46	434-435	]	_	_	_	_

#Text=He also was postdoctoral fellow at the Joslin Diabetes Center [ 2 ] and is coordinator of the Obesity and Comorbidities Research Center at the University of Campinas . [ 3 ]
9-1	436-438	He	person	giv	ana	11-3
9-2	439-443	also	_	_	_	_
9-3	444-447	was	_	_	_	_
9-4	448-460	postdoctoral	_	_	_	_
9-5	461-467	fellow	_	_	_	_
9-6	468-470	at	_	_	_	_
9-7	471-474	the	person[34]	new[34]	coref	9-18[40_34]
9-8	475-481	Joslin	person[34]	new[34]	_	_
9-9	482-490	Diabetes	abstract|person[34]	new|new[34]	coref	11-6[48_0]
9-10	491-497	Center	person[34]	new[34]	_	_
9-11	498-499	[	_	_	_	_
9-12	500-501	2	quantity	new	_	_
9-13	502-503	]	_	_	_	_
9-14	504-507	and	_	_	_	_
9-15	508-510	is	_	_	_	_
9-16	511-522	coordinator	person[36]	new[36]	_	_
9-17	523-525	of	person[36]	new[36]	_	_
9-18	526-529	the	person[36]|person[40]	new[36]|giv[40]	_	_
9-19	530-537	Obesity	person[36]|abstract|person[40]	new[36]|new|giv[40]	coref	12-5[57_0]
9-20	538-541	and	person[36]|person[40]	new[36]|giv[40]	_	_
9-21	542-555	Comorbidities	person[36]|place|person[40]	new[36]|new|giv[40]	_	_
9-22	556-564	Research	person[36]|organization|person[40]	new[36]|new|giv[40]	coref	10-1
9-23	565-571	Center	person[36]|person[40]	new[36]|giv[40]	_	_
9-24	572-574	at	person[36]|person[40]	new[36]|giv[40]	_	_
9-25	575-578	the	person[36]|person[40]|organization[41]	new[36]|giv[40]|giv[41]	_	_
9-26	579-589	University	person[36]|person[40]|organization[41]	new[36]|giv[40]|giv[41]	_	_
9-27	590-592	of	person[36]|person[40]|organization[41]	new[36]|giv[40]|giv[41]	_	_
9-28	593-601	Campinas	person[36]|person[40]|organization[41]|place	new[36]|giv[40]|giv[41]|giv	_	_
9-29	602-603	.	_	_	_	_
9-30	604-605	[	_	_	_	_
9-31	606-607	3	abstract	new	coref	25-49
9-32	608-609	]	_	_	_	_

#Text=Research
10-1	610-618	Research	abstract	giv	coref	23-1[126_0]

#Text=In 2001 he studied type 2 diabetes along with Claudio Teodoro de Souza , a back-then Ph.D. student at the Cell Signaling Laboratory .
11-1	619-621	In	_	_	_	_
11-2	622-626	2001	time	new	_	_
11-3	627-629	he	person	giv	coref	13-3[62_0]
11-4	630-637	studied	event	new	coref|none	25-17[153_0]|11-4[0_153]
11-5	638-642	type	abstract	new	_	_
11-6	643-644	2	abstract[48]	giv[48]	coref	19-13[0_48]
11-7	645-653	diabetes	abstract[48]	giv[48]	_	_
11-8	654-659	along	_	_	_	_
11-9	660-664	with	_	_	_	_
11-10	665-672	Claudio	person[49]	new[49]	appos	11-15[51_49]
11-11	673-680	Teodoro	person[49]	new[49]	_	_
11-12	681-683	de	person[49]	new[49]	_	_
11-13	684-689	Souza	person[49]	new[49]	_	_
11-14	690-691	,	_	_	_	_
11-15	692-693	a	person[51]	giv[51]	coref	16-6[0_51]
11-16	694-703	back-then	person[51]	giv[51]	_	_
11-17	704-709	Ph.D.	abstract|person[51]	new|giv[51]	_	_
11-18	710-717	student	person[51]	giv[51]	_	_
11-19	718-720	at	person[51]	giv[51]	_	_
11-20	721-724	the	person[51]|organization[54]	giv[51]|new[54]	_	_
11-21	725-729	Cell	person[51]|person|organization[54]	giv[51]|new|new[54]	_	_
11-22	730-739	Signaling	person[51]|object|organization[54]	giv[51]|new|new[54]	_	_
11-23	740-750	Laboratory	person[51]|organization[54]	giv[51]|new[54]	_	_
11-24	751-752	.	_	_	_	_

#Text=Their study revealed that the disease reoccurs when pancreas fail to supply the peripheral need for insulin that the body needs .
12-1	753-758	Their	person|event[56]	acc|new[56]	coref	21-2[113_56]
12-2	759-764	study	event[56]	new[56]	_	_
12-3	765-773	revealed	_	_	_	_
12-4	774-778	that	_	_	_	_
12-5	779-782	the	abstract[57]	giv[57]	coref	20-15[0_57]
12-6	783-790	disease	abstract[57]	giv[57]	_	_
12-7	791-799	reoccurs	_	_	_	_
12-8	800-804	when	_	_	_	_
12-9	805-813	pancreas	object	new	coref	13-9[63_0]
12-10	814-818	fail	_	_	_	_
12-11	819-821	to	_	_	_	_
12-12	822-828	supply	_	_	_	_
12-13	829-832	the	abstract[59]	new[59]	coref	13-16[65_59]
12-14	833-843	peripheral	abstract[59]	new[59]	_	_
12-15	844-848	need	abstract[59]	new[59]	_	_
12-16	849-852	for	abstract[59]	new[59]	_	_
12-17	853-860	insulin	abstract[59]|substance[60]	new[59]|new[60]	coref	13-13[0_60]
12-18	861-865	that	abstract[59]|substance[60]	new[59]|new[60]	_	_
12-19	866-869	the	abstract[59]|substance[60]|object[61]	new[59]|new[60]|new[61]	_	_
12-20	870-874	body	abstract[59]|substance[60]|object[61]	new[59]|new[60]|new[61]	_	_
12-21	875-880	needs	abstract[59]|substance[60]	new[59]|new[60]	_	_
12-22	881-882	.	_	_	_	_

#Text=According to Lício Velloso , as long as the pancreas can produce insulin to maintain this need , the blood glucose level remains stable - close to 80 , 90 , expected for a healthy person .
13-1	883-892	According	_	_	_	_
13-2	893-895	to	_	_	_	_
13-3	896-901	Lício	person[62]	giv[62]	coref	26-3[0_62]
13-4	902-909	Velloso	person[62]	giv[62]	_	_
13-5	910-911	,	_	_	_	_
13-6	912-914	as	_	_	_	_
13-7	915-919	long	_	_	_	_
13-8	920-922	as	_	_	_	_
13-9	923-926	the	object[63]	giv[63]	_	_
13-10	927-935	pancreas	object[63]	giv[63]	_	_
13-11	936-939	can	_	_	_	_
13-12	940-947	produce	_	_	_	_
13-13	948-955	insulin	substance	giv	coref	14-18
13-14	956-958	to	_	_	_	_
13-15	959-967	maintain	_	_	_	_
13-16	968-972	this	abstract[65]	giv[65]	ana	14-4[0_65]
13-17	973-977	need	abstract[65]	giv[65]	_	_
13-18	978-979	,	_	_	_	_
13-19	980-983	the	abstract[68]	new[68]	_	_
13-20	984-989	blood	substance|abstract[68]	new|new[68]	coref	25-38[159_0]
13-21	990-997	glucose	substance|abstract[68]	new|new[68]	coref	14-8[73_0]
13-22	998-1003	level	abstract[68]	new[68]	_	_
13-23	1004-1011	remains	_	_	_	_
13-24	1012-1018	stable	_	_	_	_
13-25	1019-1020	-	_	_	_	_
13-26	1021-1026	close	_	_	_	_
13-27	1027-1029	to	_	_	_	_
13-28	1030-1032	80	quantity	new	_	_
13-29	1033-1034	,	_	_	_	_
13-30	1035-1037	90	quantity	new	_	_
13-31	1038-1039	,	_	_	_	_
13-32	1040-1048	expected	_	_	_	_
13-33	1049-1052	for	_	_	_	_
13-34	1053-1054	a	person[71]	new[71]	_	_
13-35	1055-1062	healthy	person[71]	new[71]	_	_
13-36	1063-1069	person	person[71]	new[71]	_	_
13-37	1070-1071	.	_	_	_	_

#Text=But , when it does fail , the glucose rises , which makes a patient dependent on insulin .
14-1	1072-1075	But	_	_	_	_
14-2	1076-1077	,	_	_	_	_
14-3	1078-1082	when	_	_	_	_
14-4	1083-1085	it	abstract	giv	_	_
14-5	1086-1090	does	_	_	_	_
14-6	1091-1095	fail	_	_	_	_
14-7	1096-1097	,	_	_	_	_
14-8	1098-1101	the	substance[73]	giv[73]	coref	23-20[132_73]
14-9	1102-1109	glucose	substance[73]	giv[73]	_	_
14-10	1110-1115	rises	_	_	_	_
14-11	1116-1117	,	_	_	_	_
14-12	1118-1123	which	_	_	_	_
14-13	1124-1129	makes	_	_	_	_
14-14	1130-1131	a	person[74]	new[74]	_	_
14-15	1132-1139	patient	person[74]	new[74]	_	_
14-16	1140-1149	dependent	_	_	_	_
14-17	1150-1152	on	_	_	_	_
14-18	1153-1160	insulin	substance	giv	coref	18-22
14-19	1161-1162	.	_	_	_	_

#Text=This dependency can result into hyperinsulinemic hypoglycemia , according to Velloso .
15-1	1163-1167	This	abstract[76]	new[76]	_	_
15-2	1168-1178	dependency	abstract[76]	new[76]	_	_
15-3	1179-1182	can	_	_	_	_
15-4	1183-1189	result	abstract	new	coref|none	17-2[86_0]|15-4[0_86]
15-5	1190-1194	into	_	_	_	_
15-6	1195-1211	hyperinsulinemic	abstract|abstract[78]	new|new[78]	_	_
15-7	1212-1224	hypoglycemia	abstract[78]	new[78]	_	_
15-8	1225-1226	,	_	_	_	_
15-9	1227-1236	according	_	_	_	_
15-10	1237-1239	to	_	_	_	_
15-11	1240-1247	Velloso	place	giv	coref	16-2[80_0]
15-12	1248-1249	.	_	_	_	_

#Text=Under Velloso 's guidance , Souza had studied alpha protein and injected it with an insulin-producing cell .
16-1	1250-1255	Under	_	_	_	_
16-2	1256-1263	Velloso	place[80]|abstract[81]	giv[80]|new[81]	ana	17-11[0_80]
16-3	1264-1266	's	place[80]|abstract[81]	giv[80]|new[81]	_	_
16-4	1267-1275	guidance	abstract[81]	new[81]	_	_
16-5	1276-1277	,	_	_	_	_
16-6	1278-1283	Souza	person	giv	_	_
16-7	1284-1287	had	_	_	_	_
16-8	1288-1295	studied	_	_	_	_
16-9	1296-1301	alpha	substance[83]	new[83]	ana	16-13[0_83]
16-10	1302-1309	protein	substance[83]	new[83]	_	_
16-11	1310-1313	and	_	_	_	_
16-12	1314-1322	injected	_	_	_	_
16-13	1323-1325	it	substance	giv	coref	18-18[97_0]
16-14	1326-1330	with	_	_	_	_
16-15	1331-1333	an	object[85]	new[85]	_	_
16-16	1334-1351	insulin-producing	object[85]	new[85]	_	_
16-17	1352-1356	cell	object[85]	new[85]	_	_
16-18	1357-1358	.	_	_	_	_

#Text=While the result did n't yield a major breakthrough , it opened a possibility of developing a drug that would reduce the action of PPARGC1A .
17-1	1359-1364	While	_	_	_	_
17-2	1365-1368	the	abstract[86]	new[86]	_	_
17-3	1369-1375	result	abstract[86]	new[86]	_	_
17-4	1376-1379	did	_	_	_	_
17-5	1380-1383	n't	_	_	_	_
17-6	1384-1389	yield	_	_	_	_
17-7	1390-1391	a	abstract[87]	new[87]	_	_
17-8	1392-1397	major	abstract[87]	new[87]	_	_
17-9	1398-1410	breakthrough	abstract[87]	new[87]	_	_
17-10	1411-1412	,	_	_	_	_
17-11	1413-1415	it	place	giv	coref	26-4
17-12	1416-1422	opened	_	_	_	_
17-13	1423-1424	a	abstract[89]	new[89]	_	_
17-14	1425-1436	possibility	abstract[89]	new[89]	_	_
17-15	1437-1439	of	_	_	_	_
17-16	1440-1450	developing	_	_	_	_
17-17	1451-1452	a	object[90]	new[90]	ana	19-4[0_90]
17-18	1453-1457	drug	object[90]	new[90]	_	_
17-19	1458-1462	that	_	_	_	_
17-20	1463-1468	would	_	_	_	_
17-21	1469-1475	reduce	_	_	_	_
17-22	1476-1479	the	abstract[91]	new[91]	ana	18-11[0_91]
17-23	1480-1486	action	abstract[91]	new[91]	_	_
17-24	1487-1489	of	abstract[91]	new[91]	_	_
17-25	1490-1498	PPARGC1A	abstract[91]|substance	new[91]|new	_	_
17-26	1499-1500	.	_	_	_	_

#Text=During the trials , which the duo conducted revealed that it does indeed reduces the production of alpha protein while increases insulin production .
18-1	1501-1507	During	_	_	_	_
18-2	1508-1511	the	event[93]	new[93]	_	_
18-3	1512-1518	trials	event[93]	new[93]	_	_
18-4	1519-1520	,	_	_	_	_
18-5	1521-1526	which	_	_	_	_
18-6	1527-1530	the	person[94]	new[94]	ana	20-5[0_94]
18-7	1531-1534	duo	person[94]	new[94]	_	_
18-8	1535-1544	conducted	_	_	_	_
18-9	1545-1553	revealed	_	_	_	_
18-10	1554-1558	that	_	_	_	_
18-11	1559-1561	it	abstract	giv	coref	24-11[140_0]
18-12	1562-1566	does	_	_	_	_
18-13	1567-1573	indeed	_	_	_	_
18-14	1574-1581	reduces	_	_	_	_
18-15	1582-1585	the	abstract[96]	new[96]	coref	18-22[99_96]
18-16	1586-1596	production	abstract[96]	new[96]	_	_
18-17	1597-1599	of	abstract[96]	new[96]	_	_
18-18	1600-1605	alpha	abstract[96]|substance[97]	new[96]|giv[97]	_	_
18-19	1606-1613	protein	abstract[96]|substance[97]	new[96]|giv[97]	_	_
18-20	1614-1619	while	_	_	_	_
18-21	1620-1629	increases	_	_	_	_
18-22	1630-1637	insulin	substance|abstract[99]	giv|giv[99]	coref|coref	19-6|19-6[102_99]
18-23	1638-1648	production	abstract[99]	giv[99]	_	_
18-24	1649-1650	.	_	_	_	_

#Text=Not only did it increase insulin production , but it also decrease diabetes occurrence . [ 4 ]
19-1	1651-1654	Not	_	_	_	_
19-2	1655-1659	only	_	_	_	_
19-3	1660-1663	did	_	_	_	_
19-4	1664-1666	it	object	giv	ana	19-10
19-5	1667-1675	increase	_	_	_	_
19-6	1676-1683	insulin	substance|abstract[102]	giv|giv[102]	_	_
19-7	1684-1694	production	abstract[102]	giv[102]	_	_
19-8	1695-1696	,	_	_	_	_
19-9	1697-1700	but	_	_	_	_
19-10	1701-1703	it	object	giv	_	_
19-11	1704-1708	also	_	_	_	_
19-12	1709-1717	decrease	_	_	_	_
19-13	1718-1726	diabetes	abstract|abstract[105]	giv|new[105]	coref	24-24
19-14	1727-1737	occurrence	abstract[105]	new[105]	_	_
19-15	1738-1739	.	_	_	_	_
19-16	1740-1741	[	_	_	_	_
19-17	1742-1743	4	abstract	new	_	_
19-18	1744-1745	]	_	_	_	_

#Text=For two years , he and Marciane Milanski , a nutritionist , had studied obesity in rats .
20-1	1746-1749	For	_	_	_	_
20-2	1750-1753	two	time[107]	new[107]	_	_
20-3	1754-1759	years	time[107]	new[107]	_	_
20-4	1760-1761	,	_	_	_	_
20-5	1762-1764	he	person	giv	_	_
20-6	1765-1768	and	_	_	_	_
20-7	1769-1777	Marciane	person[109]	new[109]	appos	20-10[110_109]
20-8	1778-1786	Milanski	person[109]	new[109]	_	_
20-9	1787-1788	,	_	_	_	_
20-10	1789-1790	a	person[110]	giv[110]	_	_
20-11	1791-1803	nutritionist	person[110]	giv[110]	_	_
20-12	1804-1805	,	_	_	_	_
20-13	1806-1809	had	_	_	_	_
20-14	1810-1817	studied	_	_	_	_
20-15	1818-1825	obesity	abstract	giv	ana	21-5
20-16	1826-1828	in	_	_	_	_
20-17	1829-1833	rats	animal	new	_	_
20-18	1834-1835	.	_	_	_	_

#Text=During the study , it was suggested that it is possible to make brain control liver in order to maintain glycemic balance .
21-1	1836-1842	During	_	_	_	_
21-2	1843-1846	the	event[113]	giv[113]	coref	27-2[170_113]
21-3	1847-1852	study	event[113]	giv[113]	_	_
21-4	1853-1854	,	_	_	_	_
21-5	1855-1857	it	abstract	giv	coref	32-24
21-6	1858-1861	was	_	_	_	_
21-7	1862-1871	suggested	_	_	_	_
21-8	1872-1876	that	_	_	_	_
21-9	1877-1879	it	event	new	cata	21-9[0_116]
21-10	1880-1882	is	_	_	_	_
21-11	1883-1891	possible	_	_	_	_
21-12	1892-1894	to	event[116]	new[116]	_	_
21-13	1895-1899	make	event[116]	new[116]	_	_
21-14	1900-1905	brain	event[116]|object|object[119]	new[116]|new|new[119]	ana	22-2[0_119]
21-15	1906-1913	control	event[116]|person|object[119]	new[116]|new|new[119]	_	_
21-16	1914-1919	liver	event[116]|object[119]	new[116]|new[119]	_	_
21-17	1920-1922	in	_	_	_	_
21-18	1923-1928	order	_	_	_	_
21-19	1929-1931	to	_	_	_	_
21-20	1932-1940	maintain	_	_	_	_
21-21	1941-1949	glycemic	abstract|abstract[121]	new|new[121]	_	_
21-22	1950-1957	balance	abstract[121]	new[121]	_	_
21-23	1958-1959	.	_	_	_	_

#Text=When it does happen , the hypothalamus becomes the main actor of this mechanism .
22-1	1960-1964	When	_	_	_	_
22-2	1965-1967	it	object	giv	coref	28-30
22-3	1968-1972	does	_	_	_	_
22-4	1973-1979	happen	_	_	_	_
22-5	1980-1981	,	_	_	_	_
22-6	1982-1985	the	object[123]	new[123]	coref	23-33[134_123]
22-7	1986-1998	hypothalamus	object[123]	new[123]	_	_
22-8	1999-2006	becomes	_	_	_	_
22-9	2007-2010	the	person[124]	new[124]	ana	23-6[0_124]
22-10	2011-2015	main	person[124]	new[124]	_	_
22-11	2016-2021	actor	person[124]	new[124]	_	_
22-12	2022-2024	of	person[124]	new[124]	_	_
22-13	2025-2029	this	person[124]|abstract[125]	new[124]|new[125]	coref	23-10[129_125]
22-14	2030-2039	mechanism	person[124]|abstract[125]	new[124]|new[125]	_	_
22-15	2040-2041	.	_	_	_	_

#Text=The research , along with his comment : " The mechanism described by this research shows that control of high glucose in fasting is done , at least in part , by the hypothalamus .
23-1	2042-2045	The	abstract[126]	giv[126]	coref	23-14[130_126]
23-2	2046-2054	research	abstract[126]	giv[126]	_	_
23-3	2055-2056	,	abstract[126]	giv[126]	_	_
23-4	2057-2062	along	abstract[126]	giv[126]	_	_
23-5	2063-2067	with	abstract[126]	giv[126]	_	_
23-6	2068-2071	his	abstract[126]|person|abstract[128]	giv[126]|giv|new[128]	ana	25-5
23-7	2072-2079	comment	abstract[126]|abstract[128]	giv[126]|new[128]	_	_
23-8	2080-2081	:	_	_	_	_
23-9	2082-2083	"	_	_	_	_
23-10	2084-2087	The	abstract[129]	giv[129]	_	_
23-11	2088-2097	mechanism	abstract[129]	giv[129]	_	_
23-12	2098-2107	described	_	_	_	_
23-13	2108-2110	by	_	_	_	_
23-14	2111-2115	this	abstract[130]	giv[130]	_	_
23-15	2116-2124	research	abstract[130]	giv[130]	_	_
23-16	2125-2130	shows	_	_	_	_
23-17	2131-2135	that	abstract[131]	new[131]	ana	24-1[0_131]
23-18	2136-2143	control	abstract[131]	new[131]	_	_
23-19	2144-2146	of	abstract[131]	new[131]	_	_
23-20	2147-2151	high	abstract[131]|substance[132]	new[131]|giv[132]	_	_
23-21	2152-2159	glucose	abstract[131]|substance[132]	new[131]|giv[132]	_	_
23-22	2160-2162	in	abstract[131]|substance[132]	new[131]|giv[132]	_	_
23-23	2163-2170	fasting	abstract[131]|substance[132]|event	new[131]|giv[132]|new	_	_
23-24	2171-2173	is	_	_	_	_
23-25	2174-2178	done	_	_	_	_
23-26	2179-2180	,	_	_	_	_
23-27	2181-2183	at	_	_	_	_
23-28	2184-2189	least	_	_	_	_
23-29	2190-2192	in	_	_	_	_
23-30	2193-2197	part	_	_	_	_
23-31	2198-2199	,	_	_	_	_
23-32	2200-2202	by	_	_	_	_
23-33	2203-2206	the	object[134]	giv[134]	coref	25-45[161_134]
23-34	2207-2219	hypothalamus	object[134]	giv[134]	_	_
23-35	2220-2221	.	_	_	_	_

#Text=This reinforces our suspicion that the development of drugs with action in the central nervous system should be interesting for the treatment of diabetes " were published in the American Journal of Deabetes in 2012 . [ 5 ]
24-1	2222-2226	This	abstract	giv	_	_
24-2	2227-2237	reinforces	_	_	_	_
24-3	2238-2241	our	person|abstract[137]	acc|new[137]	_	_
24-4	2242-2251	suspicion	abstract[137]	new[137]	_	_
24-5	2252-2256	that	abstract[137]	new[137]	_	_
24-6	2257-2260	the	abstract[137]|abstract[138]	new[137]|new[138]	_	_
24-7	2261-2272	development	abstract[137]|abstract[138]	new[137]|new[138]	_	_
24-8	2273-2275	of	abstract[137]|abstract[138]	new[137]|new[138]	_	_
24-9	2276-2281	drugs	abstract[137]|abstract[138]|substance	new[137]|new[138]|new	_	_
24-10	2282-2286	with	abstract[137]|abstract[138]	new[137]|new[138]	_	_
24-11	2287-2293	action	abstract[137]|abstract[138]|abstract[140]	new[137]|new[138]|giv[140]	_	_
24-12	2294-2296	in	abstract[137]|abstract[138]|abstract[140]	new[137]|new[138]|giv[140]	_	_
24-13	2297-2300	the	abstract[137]|abstract[138]|abstract[140]|place[141]	new[137]|new[138]|giv[140]|new[141]	_	_
24-14	2301-2308	central	abstract[137]|abstract[138]|abstract[140]|place[141]	new[137]|new[138]|giv[140]|new[141]	_	_
24-15	2309-2316	nervous	abstract[137]|abstract[138]|abstract[140]|place[141]	new[137]|new[138]|giv[140]|new[141]	_	_
24-16	2317-2323	system	abstract[137]|abstract[138]|abstract[140]|place[141]	new[137]|new[138]|giv[140]|new[141]	_	_
24-17	2324-2330	should	abstract[137]	new[137]	_	_
24-18	2331-2333	be	abstract[137]	new[137]	_	_
24-19	2334-2345	interesting	abstract[137]	new[137]	_	_
24-20	2346-2349	for	_	_	_	_
24-21	2350-2353	the	abstract[142]	new[142]	_	_
24-22	2354-2363	treatment	abstract[142]	new[142]	_	_
24-23	2364-2366	of	abstract[142]	new[142]	_	_
24-24	2367-2375	diabetes	abstract[142]|abstract	new[142]|giv	_	_
24-25	2376-2377	"	_	_	_	_
24-26	2378-2382	were	_	_	_	_
24-27	2383-2392	published	_	_	_	_
24-28	2393-2395	in	_	_	_	_
24-29	2396-2399	the	organization[144]	new[144]	_	_
24-30	2400-2408	American	organization[144]	new[144]	_	_
24-31	2409-2416	Journal	organization[144]	new[144]	_	_
24-32	2417-2419	of	organization[144]	new[144]	_	_
24-33	2420-2428	Deabetes	organization[144]|abstract	new[144]|new	_	_
24-34	2429-2431	in	_	_	_	_
24-35	2432-2436	2012	time	new	_	_
24-36	2437-2438	.	_	_	_	_
24-37	2439-2440	[	_	_	_	_
24-38	2441-2442	5	abstract	new	_	_
24-39	2443-2444	]	_	_	_	_

#Text=From 2005 to 2007 he had studied human diet , and , according to him , the studies of various groups have shown that a diet rich in simple carbohydrates , can also increase lipid levels in the blood and indirectly promote inflammation in the hypothalamus . [ 3 ]
25-1	2445-2449	From	_	_	_	_
25-2	2450-2454	2005	time[148]	new[148]	_	_
25-3	2455-2457	to	time[148]	new[148]	_	_
25-4	2458-2462	2007	time[148]|time	new[148]|new	_	_
25-5	2463-2465	he	person	giv	ana	25-15
25-6	2466-2469	had	_	_	_	_
25-7	2470-2477	studied	_	_	_	_
25-8	2478-2483	human	event[151]	new[151]	coref	25-25[155_151]
25-9	2484-2488	diet	event[151]	new[151]	_	_
25-10	2489-2490	,	_	_	_	_
25-11	2491-2494	and	_	_	_	_
25-12	2495-2496	,	_	_	_	_
25-13	2497-2506	according	_	_	_	_
25-14	2507-2509	to	_	_	_	_
25-15	2510-2513	him	person	giv	_	_
25-16	2514-2515	,	_	_	_	_
25-17	2516-2519	the	event[153]	new[153]	_	_
25-18	2520-2527	studies	event[153]	new[153]	_	_
25-19	2528-2530	of	event[153]	new[153]	_	_
25-20	2531-2538	various	event[153]|person[154]	new[153]|new[154]	ana	26-10[0_154]
25-21	2539-2545	groups	event[153]|person[154]	new[153]|new[154]	_	_
25-22	2546-2550	have	_	_	_	_
25-23	2551-2556	shown	_	_	_	_
25-24	2557-2561	that	_	_	_	_
25-25	2562-2563	a	event[155]	giv[155]	_	_
25-26	2564-2568	diet	event[155]	giv[155]	_	_
25-27	2569-2573	rich	event[155]	giv[155]	_	_
25-28	2574-2576	in	_	_	_	_
25-29	2577-2583	simple	substance[156]	new[156]	_	_
25-30	2584-2597	carbohydrates	substance[156]	new[156]	_	_
25-31	2598-2599	,	_	_	_	_
25-32	2600-2603	can	_	_	_	_
25-33	2604-2608	also	_	_	_	_
25-34	2609-2617	increase	_	_	_	_
25-35	2618-2623	lipid	person|abstract[158]	new|new[158]	_	_
25-36	2624-2630	levels	abstract[158]	new[158]	_	_
25-37	2631-2633	in	abstract[158]	new[158]	_	_
25-38	2634-2637	the	abstract[158]|substance[159]	new[158]|giv[159]	_	_
25-39	2638-2643	blood	abstract[158]|substance[159]	new[158]|giv[159]	_	_
25-40	2644-2647	and	_	_	_	_
25-41	2648-2658	indirectly	_	_	_	_
25-42	2659-2666	promote	_	_	_	_
25-43	2667-2679	inflammation	abstract	new	_	_
25-44	2680-2682	in	_	_	_	_
25-45	2683-2686	the	object[161]	giv[161]	_	_
25-46	2687-2699	hypothalamus	object[161]	giv[161]	_	_
25-47	2700-2701	.	_	_	_	_
25-48	2702-2703	[	_	_	_	_
25-49	2704-2705	3	abstract	giv	_	_
25-50	2706-2707	]	_	_	_	_

#Text=In 2018 Lício Velloso studied hunger strikes and divided them in three categories : Absolute , total and partial .
26-1	2708-2710	In	_	_	_	_
26-2	2711-2715	2018	time	new	coref	30-5
26-3	2716-2721	Lício	person	giv	_	_
26-4	2722-2729	Velloso	person	giv	ana	27-5
26-5	2730-2737	studied	_	_	_	_
26-6	2738-2744	hunger	abstract|event[167]	new|new[167]	coref|coref	27-12|27-11[174_167]
26-7	2745-2752	strikes	event[167]	new[167]	_	_
26-8	2753-2756	and	_	_	_	_
26-9	2757-2764	divided	_	_	_	_
26-10	2765-2769	them	person	giv	ana	27-20
26-11	2770-2772	in	_	_	_	_
26-12	2773-2778	three	abstract[169]	new[169]	_	_
26-13	2779-2789	categories	abstract[169]	new[169]	_	_
26-14	2790-2791	:	_	_	_	_
26-15	2792-2800	Absolute	_	_	_	_
26-16	2801-2802	,	_	_	_	_
26-17	2803-2808	total	_	_	_	_
26-18	2809-2812	and	_	_	_	_
26-19	2813-2820	partial	_	_	_	_
26-20	2821-2822	.	_	_	_	_

#Text=During the study , he suggested that people who do partial hunger strikes could have more severe consequences then those that have the absolute one .
27-1	2823-2829	During	_	_	_	_
27-2	2830-2833	the	event[170]	giv[170]	_	_
27-3	2834-2839	study	event[170]	giv[170]	_	_
27-4	2840-2841	,	_	_	_	_
27-5	2842-2844	he	person	giv	_	_
27-6	2845-2854	suggested	_	_	_	_
27-7	2855-2859	that	_	_	_	_
27-8	2860-2866	people	person	new	coref	29-10
27-9	2867-2870	who	_	_	_	_
27-10	2871-2873	do	_	_	_	_
27-11	2874-2881	partial	event[174]	giv[174]	_	_
27-12	2882-2888	hunger	abstract|event[174]	giv|giv[174]	_	_
27-13	2889-2896	strikes	event[174]	giv[174]	_	_
27-14	2897-2902	could	_	_	_	_
27-15	2903-2907	have	_	_	_	_
27-16	2908-2912	more	abstract[175]	new[175]	_	_
27-17	2913-2919	severe	abstract[175]	new[175]	_	_
27-18	2920-2932	consequences	abstract[175]	new[175]	_	_
27-19	2933-2937	then	_	_	_	_
27-20	2938-2943	those	person	giv	_	_
27-21	2944-2948	that	_	_	_	_
27-22	2949-2953	have	_	_	_	_
27-23	2954-2957	the	abstract[177]	new[177]	coref	28-5[178_177]
27-24	2958-2966	absolute	abstract[177]	new[177]	_	_
27-25	2967-2970	one	abstract[177]	new[177]	_	_
27-26	2971-2972	.	_	_	_	_

#Text=For example , in an absolute strike only kidneys and heart fails after 25 days of being on a strike , while strikers who preferred partial ended up with liver complications within 40 to 50 days after the strike .
28-1	2973-2976	For	_	_	_	_
28-2	2977-2984	example	_	_	_	_
28-3	2985-2986	,	_	_	_	_
28-4	2987-2989	in	_	_	_	_
28-5	2990-2992	an	event[178]	giv[178]	coref	28-19[182_178]
28-6	2993-3001	absolute	event[178]	giv[178]	_	_
28-7	3002-3008	strike	event[178]	giv[178]	_	_
28-8	3009-3013	only	object[179]	new[179]	_	_
28-9	3014-3021	kidneys	object[179]	new[179]	_	_
28-10	3022-3025	and	_	_	_	_
28-11	3026-3031	heart	object	new	coref	29-13[191_0]
28-12	3032-3037	fails	_	_	_	_
28-13	3038-3043	after	_	_	_	_
28-14	3044-3046	25	time[181]	new[181]	_	_
28-15	3047-3051	days	time[181]	new[181]	_	_
28-16	3052-3054	of	_	_	_	_
28-17	3055-3060	being	_	_	_	_
28-18	3061-3063	on	_	_	_	_
28-19	3064-3065	a	event[182]	giv[182]	coref	28-38[187_182]
28-20	3066-3072	strike	event[182]	giv[182]	_	_
28-21	3073-3074	,	_	_	_	_
28-22	3075-3080	while	_	_	_	_
28-23	3081-3089	strikers	person	new	_	_
28-24	3090-3093	who	_	_	_	_
28-25	3094-3103	preferred	_	_	_	_
28-26	3104-3111	partial	_	_	_	_
28-27	3112-3117	ended	_	_	_	_
28-28	3118-3120	up	_	_	_	_
28-29	3121-3125	with	_	_	_	_
28-30	3126-3131	liver	object|abstract[185]	giv|new[185]	_	_
28-31	3132-3145	complications	abstract[185]	new[185]	_	_
28-32	3146-3152	within	abstract[185]	new[185]	_	_
28-33	3153-3155	40	abstract[185]	new[185]	_	_
28-34	3156-3158	to	_	_	_	_
28-35	3159-3161	50	time[186]	new[186]	_	_
28-36	3162-3166	days	time[186]	new[186]	_	_
28-37	3167-3172	after	time[186]	new[186]	_	_
28-38	3173-3176	the	time[186]|event[187]	new[186]|giv[187]	ana	29-24[0_187]
28-39	3177-3183	strike	time[186]|event[187]	new[186]|giv[187]	_	_
28-40	3184-3185	.	_	_	_	_

#Text=In conclusion , what Dr. Velloso suggests is that people who have a weak heart should n't take too much liquid , otherwise it can lead to heart failure and even death . [ 6 ]
29-1	3186-3188	In	_	_	_	_
29-2	3189-3199	conclusion	abstract	new	_	_
29-3	3200-3201	,	_	_	_	_
29-4	3202-3206	what	_	_	_	_
29-5	3207-3210	Dr.	person[189]	new[189]	ana	30-6[0_189]
29-6	3211-3218	Velloso	person[189]	new[189]	_	_
29-7	3219-3227	suggests	_	_	_	_
29-8	3228-3230	is	_	_	_	_
29-9	3231-3235	that	_	_	_	_
29-10	3236-3242	people	person	giv	_	_
29-11	3243-3246	who	_	_	_	_
29-12	3247-3251	have	_	_	_	_
29-13	3252-3253	a	object[191]	giv[191]	coref	29-28[0_191]
29-14	3254-3258	weak	object[191]	giv[191]	_	_
29-15	3259-3264	heart	object[191]	giv[191]	_	_
29-16	3265-3271	should	_	_	_	_
29-17	3272-3275	n't	_	_	_	_
29-18	3276-3280	take	_	_	_	_
29-19	3281-3284	too	substance[192]	new[192]	_	_
29-20	3285-3289	much	substance[192]	new[192]	_	_
29-21	3290-3296	liquid	substance[192]	new[192]	_	_
29-22	3297-3298	,	_	_	_	_
29-23	3299-3308	otherwise	_	_	_	_
29-24	3309-3311	it	event	giv	_	_
29-25	3312-3315	can	_	_	_	_
29-26	3316-3320	lead	_	_	_	_
29-27	3321-3323	to	_	_	_	_
29-28	3324-3329	heart	object|abstract[195]	giv|new[195]	_	_
29-29	3330-3337	failure	abstract[195]	new[195]	_	_
29-30	3338-3341	and	_	_	_	_
29-31	3342-3346	even	event[196]	new[196]	_	_
29-32	3347-3352	death	event[196]	new[196]	_	_
29-33	3353-3354	.	_	_	_	_
29-34	3355-3356	[	_	_	_	_
29-35	3357-3358	6	abstract	new	_	_
29-36	3359-3360	]	_	_	_	_

#Text=On October 30 , 2018 he appeared on an interview with Paulo Saldiva of Science and Health program of the Futura Chanel . [ 7 ]
30-1	3361-3363	On	_	_	_	_
30-2	3364-3371	October	time|time[199]	new|new[199]	_	_
30-3	3372-3374	30	time[199]	new[199]	_	_
30-4	3375-3376	,	time[199]	new[199]	_	_
30-5	3377-3381	2018	time[199]|time	new[199]|giv	_	_
30-6	3382-3384	he	person	giv	ana	32-1
30-7	3385-3393	appeared	_	_	_	_
30-8	3394-3396	on	_	_	_	_
30-9	3397-3399	an	event[202]	new[202]	_	_
30-10	3400-3409	interview	event[202]	new[202]	_	_
30-11	3410-3414	with	event[202]	new[202]	_	_
30-12	3415-3420	Paulo	event[202]|person[203]	new[202]|new[203]	_	_
30-13	3421-3428	Saldiva	event[202]|person[203]	new[202]|new[203]	_	_
30-14	3429-3431	of	event[202]|person[203]	new[202]|new[203]	_	_
30-15	3432-3439	Science	event[202]|person[203]|organization	new[202]|new[203]|new	_	_
30-16	3440-3443	and	event[202]	new[202]	_	_
30-17	3444-3450	Health	event[202]|abstract|abstract[206]	new[202]|new|new[206]	_	_
30-18	3451-3458	program	event[202]|abstract[206]	new[202]|new[206]	_	_
30-19	3459-3461	of	event[202]|abstract[206]	new[202]|new[206]	_	_
30-20	3462-3465	the	event[202]|abstract[206]|organization[208]	new[202]|new[206]|new[208]	_	_
30-21	3466-3472	Futura	event[202]|abstract[206]|object|organization[208]	new[202]|new[206]|new|new[208]	_	_
30-22	3473-3479	Chanel	event[202]|abstract[206]|organization[208]	new[202]|new[206]|new[208]	_	_
30-23	3480-3481	.	_	_	_	_
30-24	3482-3483	[	_	_	_	_
30-25	3484-3485	7	abstract	new	_	_
30-26	3486-3487	]	_	_	_	_

#Text=Editorial work
31-1	3488-3497	Editorial	place|abstract[211]	new|new[211]	_	_
31-2	3498-3502	work	abstract[211]	new[211]	_	_

#Text=He is a former member of the editorial board of Clinical Endocrinology and current member of the editorial board of International Journal of Obesity . [ 8 ]
32-1	3503-3505	He	person	giv	coref	32-3[213_0]
32-2	3506-3508	is	_	_	_	_
32-3	3509-3510	a	person[213]	giv[213]	_	_
32-4	3511-3517	former	person[213]	giv[213]	_	_
32-5	3518-3524	member	person[213]	giv[213]	_	_
32-6	3525-3527	of	person[213]	giv[213]	_	_
32-7	3528-3531	the	person[213]|person[214]	giv[213]|new[214]	_	_
32-8	3532-3541	editorial	person[213]|person[214]	giv[213]|new[214]	_	_
32-9	3542-3547	board	person[213]|person[214]	giv[213]|new[214]	_	_
32-10	3548-3550	of	person[213]|person[214]	giv[213]|new[214]	_	_
32-11	3551-3559	Clinical	person[213]|person[214]|abstract[215]	giv[213]|new[214]|new[215]	_	_
32-12	3560-3573	Endocrinology	person[213]|person[214]|abstract[215]	giv[213]|new[214]|new[215]	_	_
32-13	3574-3577	and	person[213]	giv[213]	_	_
32-14	3578-3585	current	person[213]|person[216]	giv[213]|new[216]	_	_
32-15	3586-3592	member	person[213]|person[216]	giv[213]|new[216]	_	_
32-16	3593-3595	of	person[213]|person[216]	giv[213]|new[216]	_	_
32-17	3596-3599	the	person[213]|person[216]|organization[217]	giv[213]|new[216]|new[217]	_	_
32-18	3600-3609	editorial	person[213]|person[216]|organization[217]	giv[213]|new[216]|new[217]	_	_
32-19	3610-3615	board	person[213]|person[216]|organization[217]	giv[213]|new[216]|new[217]	_	_
32-20	3616-3618	of	person[213]|person[216]|organization[217]	giv[213]|new[216]|new[217]	_	_
32-21	3619-3632	International	person[213]|person[216]|organization[217]|organization[218]	giv[213]|new[216]|new[217]|new[218]	_	_
32-22	3633-3640	Journal	person[213]|person[216]|organization[217]|organization[218]	giv[213]|new[216]|new[217]|new[218]	_	_
32-23	3641-3643	of	person[213]|person[216]|organization[217]|organization[218]	giv[213]|new[216]|new[217]|new[218]	_	_
32-24	3644-3651	Obesity	person[213]|person[216]|organization[217]|organization[218]|abstract	giv[213]|new[216]|new[217]|new[218]|giv	_	_
32-25	3652-3653	.	_	_	_	_
32-26	3654-3655	[	_	_	_	_
32-27	3656-3657	8	abstract	new	_	_
32-28	3658-3659	]	_	_	_	_
